Beacon Biosignals Reports Novel Sleep EEG Results from Multiple Industry Collaborations at the American Epilepsy Society Annual MeetingBOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals, the global leader in at-home EEG and AI-powered brain health analytics, presented two scientific posters at the American Epilepsy Society (AES) Annual Meeting. These posters highlight groundbreaking work resulting from collaborations with both Longboard Pharmaceuticals and UCB, focusing on advancing understanding of sleep disturbances in individuals with Lennox-Gastaut Syndrome (LGS) and their caregivers.
Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for ObesityBOSTON and SAN DIEGO, July 24, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in at-home sleep monitoring and computational neurodiagnostics, today announced a strategic collaboration with Skye Bioscience, Inc. (Nasdaq: SKYE), a pharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, to enhance its upcoming CBEYOND™ Phase 2 clinical trial of Nimacimab. This partnership will incorporate sleep quality and sleep apnea endpoints via the Beacon Platform and the FDA 510(k)-cleared Dreem 3S EEG device to better understand the comprehensive impact of Nimacimab on patients with obesity.
Beacon Biosignals Selected by Longboard Pharmaceuticals to Advance Understanding of Epilepsy and Related ConditionsCollaboration will initially focus on the role of sleep endpoints in clinical trials relating to rare epilepsy syndromes
Beacon Biosignals and Takeda Launch Strategic Collaboration to Advance Neurobiomarkers and Endpoints for Sleep DisordersCollaboration leverages Beacon’s FDA-cleared at-home EEG headband and artificial intelligence platform to support development of novel precision therapies and improve the diagnostic journey for patients
